# MEK inhibitors are effective in Erdheim–Chester disease regardless of MAPK pathway mutations

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/mek-inhibitors-are-effective-in-erdheim-chester-disease-regardless-of-mapk/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Francesco Pegoraro,Fleur Cohen-Aubart,Matthias Papo,Francesco Catamerò,Jérôme Razanamahery,Zahir Amoura,Jean‐François Emile,Augusto Vaglio,Julien Haroche |
| Citations | 5 |
| DOI | 10.1038/s41375-025-02614-6 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://www.nature.com/articles/s41375-025-02614-6.pdf |
| OpenAlex ID | https://openalex.org/W4409726468 |
| PMID | 40269272 |
| Type | article |
| Year | 2025 |

## Paper authors

- [Augusto Vaglio](https://scholariq.org/researchers/augusto-vaglio/)

## Paper primary topic

- [Histiocytic Disorders and Treatments](https://scholariq.org/topics/histiocytic-disorders-and-treatments/)

## Paper topics

- [Histiocytic Disorders and Treatments](https://scholariq.org/topics/histiocytic-disorders-and-treatments/)
- [Eosinophilic Disorders and Syndromes](https://scholariq.org/topics/eosinophilic-disorders-and-syndromes/)
- [Myeloproliferative Neoplasms: Diagnosis and Treatment](https://scholariq.org/topics/myeloproliferative-neoplasms-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.